Malignant neoplasm of breast
Information
- Disease name
- Malignant neoplasm of breast
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03435952 | Active, not recruiting | Phase 1 | Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | July 10, 2018 | October 1, 2024 |
| NCT05033756 | Active, not recruiting | Phase 2 | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | July 30, 2022 | February 2026 |
| NCT03162627 | Active, not recruiting | Phase 1 | Selumetinib and Olaparib in Solid Tumors | August 4, 2017 | August 30, 2026 |
| NCT03429907 | Active, not recruiting | N/A | An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer | December 5, 2017 | April 30, 2026 |
| NCT02187991 | Active, not recruiting | Phase 2 | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | February 12, 2015 | December 2023 |
| NCT02204098 | Active, not recruiting | Phase 1 | Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy | January 7, 2015 | August 31, 2028 |
| NCT03379428 | Active, not recruiting | Phase 1/Phase 2 | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | November 29, 2017 | June 2024 |
| NCT05364450 | Active, not recruiting | N/A | Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors | July 17, 2021 | August 1, 2024 |
| NCT02891681 | Completed | N/A | Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment | November 29, 2016 | January 23, 2020 |
| NCT01639911 | Completed | Phase 1 | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | August 14, 2013 | July 28, 2016 |
| NCT03289819 | Completed | Phase 2 | Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC | March 23, 2018 | January 22, 2021 |
| NCT03366428 | Completed | Phase 1 | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | December 26, 2017 | February 19, 2021 |
| NCT03425656 | Completed | Phase 3 | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer | July 9, 2016 | August 5, 2018 |
| NCT03159195 | Completed | Ibrance Real World Insights | June 12, 2017 | June 24, 2021 | |
| NCT05159778 | Completed | Phase 2 | Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) | November 9, 2021 | April 12, 2023 |
| NCT01953003 | Completed | Phase 3 | Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | September 2013 | July 2017 |
| NCT02101385 | Completed | Phase 2 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | April 3, 2014 | September 9, 2022 |
| NCT02378337 | Completed | Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality | September 2014 | March 2016 | |
| NCT02408393 | Completed | Phase 3 | MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery | March 27, 2015 | March 9, 2019 |
| NCT02495363 | Completed | Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients | March 2015 | May 2017 | |
| NCT02611544 | Completed | N/A | Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors | December 2015 | December 1, 2016 |
| NCT04327063 | Completed | Phase 3 | MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery | August 4, 2020 | January 28, 2022 |
| NCT05486520 | Enrolling by invitation | N/A | Low-field MRI for Breast Cancer Screening | September 1, 2022 | September 1, 2024 |
| NCT06251544 | Not yet recruiting | Phase 1 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | January 2025 | January 2034 |
| NCT03463954 | Recruiting | N/A | Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | August 9, 2023 | September 30, 2025 |
| NCT04654208 | Recruiting | Swedish Ibrance Registries Insights (SIRI) | December 15, 2020 | August 31, 2024 | |
| NCT04669873 | Recruiting | N/A | Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery | March 4, 2021 | December 31, 2026 |
| NCT02131506 | Terminated | Phase 1 | A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer | December 2009 | January 2016 |
| NCT01395706 | Unknown status | Phase 2 | ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes | September 2011 | March 2012 |
| NCT01641003 | Unknown status | Isolation and Characterization of Cancer Stem Cells Using iFP Technique | July 2012 | June 2015 | |
| NCT05133674 | Unknown status | Phase 2 | Therapeutic Dose Monitoring (TDM) of Tamoxifen | April 4, 2022 | March 1, 2023 |
| NCT03261323 | Withdrawn | N/A | Breast Reconstruction Following Breast Cancer in Very High Risk Patients | May 31, 2019 | July 2022 |
| NCT02915172 | Withdrawn | Phase 1 | Lenvatinib and Capecitabine in Patients With Advanced Malignancies | December 2016 |
- ICD10 preferred id (Insert disease from ICD10)
- D0002057
- ICD10 preferred id (Insert disease from ICD10)
- D0002058
- ICD10 class code (Insert disease from ICD10)
- ICD10 class code (Insert disease from ICD10)
- C50